National Cancer Center Hospital, Tokyo, Japan.
Pancreas. 2011 Apr;40(3):415-21. doi: 10.1097/MPA.0b013e3182021376.
To identify prognostic factors in patients with metastatic pancreatic adenocarcinoma.
The relationship between patient characteristics and outcome was examined by multivariate regression analyses of data from 409 consecutive patients with metastatic pancreatic adenocarcinoma who had been treated with a gemcitabine-containing regimen, and we stratified the patients into 3 risk groups according to the number of prognostic factors they had for a poor outcome. A validation data set obtained from 145 patients who had been treated with agents other than gemcitabine was analyzed. The prognostic index was applied the each of the patients.
The multivariate regression analyses revealed that the presence of pain, peritoneal dissemination, liver metastasis, and an elevated serum C-reactive protein value significantly contributed to a shorter survival time. The patients were stratified into 3 groups according to their number of risk factors, and their outcomes of the 3 groups were significantly different. When the prognostic index was applied to the validation data set, the respective outcomes of the 3 groups were found to be significantly differed from each other.
Pain, peritoneal dissemination, liver metastasis, and an elevated serum C-reactive protein value are important prognostic factors for patients with metastatic pancreatic adenocarcinoma.
确定转移性胰腺腺癌患者的预后因素。
通过对 409 例接受含吉西他滨方案治疗的转移性胰腺腺癌患者的数据进行多变量回归分析，研究患者特征与预后之间的关系，并根据患者预后不良的预后因素数量将其分为 3 个风险组。对接受吉西他滨以外药物治疗的 145 例患者的验证数据集进行了分析。对每个患者应用了预后指数。
多变量回归分析显示，疼痛、腹膜扩散、肝转移和血清 C 反应蛋白升高显著影响生存时间。根据风险因素的数量，将患者分为 3 组，3 组的预后结果有显著差异。当将预后指数应用于验证数据集时，发现 3 组的各自预后结果存在显著差异。
疼痛、腹膜扩散、肝转移和血清 C 反应蛋白升高是转移性胰腺腺癌患者的重要预后因素。
